NCT06735209View on ClinicalTrials.gov

First-in-Human PfSPZ-LARC2 Vaccination/CHMI

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 23, 2025

Primary Completion Date

February 1, 2027

Study Completion Date

March 30, 2027

Conditions
Malaria
Interventions
BIOLOGICAL

PfSPZ Vaccine

PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.

BIOLOGICAL

PfSPZ (7G8) Challenge

PfSPZ (7G8) Challenge consists of cryopreserved Plasmodium falciparum (Pf) sporozoites (SPZ) that have been developed to be used to infect volunteers in controlled human malaria infection (CHMI) to assess the efficacy of antimalarial drugs and vaccines. The PfSPZ Challenge (7G8) contains a laboratory malaria clone derived from Brazil.

OTHER

Sodium Chloride, 0.9%

0.9% Sodium Chloride Injection

Trial Locations (1)

98104

The University of Washington - Virology Research Clinic, Seattle

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH